Please login to the form below

Not currently logged in
Email:
Password:

J&J's Invokana receives new FDA safety warning

Additional trial data highlights bone problems
Johnson and Johson logo

Johnson & Johnson's Invokana has suffered a major setback as the FDA strengthened its warnings about the drug's effect on bone fractures.

The FDA's warnings state that the drug is related to an increased risk of bone fracture and added new information about its effect on bone mineral density.

Clinical trials of Invokana (canaglifozin) in 714 elderly patients showed that the drug caused a significantly greater loss of bone mineral density at the hip and lower spine than placebo. Fractures occurred as soon as 12 weeks after commencing the drug.

Invokana is a sodium-glucose cotransporter-2 (SGLT2) inhibitor used for type II diabetes and works by causing blood sugar to leave the body primarily through urine.

The drug was approved by the FDA in 2013 and was predicted to reach blockbuster status, with sales of $596m in the first half of this year. 

But the additional FDA warning could reduce its competitiveness as Invokana is already under pressure from Lilly and Boehringer Inglehiem's rival SGLT2 inhibitor.

The companies' Jardiance (empaglifozin) was just last month able to claim itself as the first diabetes drug able to lower risk of heart attack, stroke and cardiovascular disease, giving it a further edge over its competition.

However the FDA said in a statement: “We are continuing to evaluate the risk of bone fractures with other drugs in the SGLT2 inhibitor class, including dapaglifozin (Farxia, Xigduo XR) and empagliflozin (Jardiance, Glyxambi, Synjardy) to determine if additional label changes or studies are needed.”

The US regulator urged health care professionals and patients to report side effects involving Invokana or other SGLT2 inhibitors, to its FDA MedWatch programme. 

Article by
Nikhil Patel

16th September 2015

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics